Recondraw
EN

GLOW blend

A mix of three separate compounds sold together in one vial: BPC-157, TB-500 and GHK-Cu. None of the three is approved as a medicine. There are no published studies of this combination, in people or in animals.

Not approved · research onlyWADA Contains substances prohibited at all times (BPC-157 under S0, TB-500 under S2)Checked October 2026
Open the GLOW blend calculatorSources

Approval status

None of the three parts is approved as a medicine in any country. FDA’s compounding reviews cover each part on its own, not this mix. See each part for its status.123

What it’s used or studied for

There are no published studies of this combination itself. See the page for each part.

Each label shows how strong the evidence is: an approved use, human studies, animal or lab studies only, or a popular claim with no published studies. Being studied is not the same as being proven safe or effective.

Side effects

There are no studies of this combination.

A blend carries the side effects and cautions of each of its parts.

What it’s made of

Type
Blend
  • BPC-157 Synthetic gastric pentadecapeptide
  • TB-500 Thymosin β4 analog
  • GHK-Cu Copper-binding tripeptide

A physical mix of separately made compounds in one vial. They are not chemically joined.

This page summarizes published information. It is not medical advice and doesn’t recommend using any compound. Many of these compounds are sold for research only. Talk to a licensed clinician.

Sources

  1. FDA: Bulk drug substances used in compounding that may present significant safety risks (current as of April 2026)
  2. FDA: Bulk drug substances nominated for compounding under section 503A, categories 1 to 3 (updated May 14, 2026)
  3. World Anti-Doping Agency: 2026 Prohibited List (in force from January 1, 2026)

Spotted a mistake on this page? Report it. The email opens with the peptide and vial already filled in.